Butorphanol tartrate Property

Melting point:

217-219°

alpha 

D22 -64.0° (c = 0.4 in methanol)

storage temp. 

2-8°C

CAS DataBase Reference

58786-99-5(CAS DataBase Reference)

Safety

Hazard Codes 

Xn

Risk Statements 

22-63

Safety Statements 

22-26-36/37/39

RIDADR 

1544

WGK Germany 

3

RTECS 

QC7795000

HazardClass 

6.1(a)

PackingGroup 

II

HS Code 

2933492250

Toxicity

LD50 in mice, rats (mg/kg): 40-57, 17-20 i.v.; 395-527, 570-756 orally (Heel)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H361Suspected of damaging fertility or the unborn child

Precautionary statements

P201Obtain special instructions before use.

P308+P313IF exposed or concerned: Get medical advice/attention.

Butorphanol tartrate Chemical Properties,Usage,Production

Description

Butorphanol (tartrate) (Item No. 23812) is an analytical reference material categorized as an opioid. Butorphanol is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.

Uses

Analgesic; antitussive.

Definition

ChEBI: The (S,S)-tartaric acid salt of butorphanol. It is used for relief or moderate to severe pain.

brand name

Stadol (Bristol-Myers Squibb).

Biochem/physiol Actions

κ/μ opioid receptor agonist.

Mechanism of action

Butorphanol is a strong agonist at κ opioid receptors, and through this interaction, it is five times more potent than morphine as an analgesic. The κagonists have a lower ceiling analgesic effect than full μ agonists; thus, they are not as effective in treating severe pain. Butorphanol is an antagonist at μ opioid receptors with approximately one-sixth the potency of naloxone. If given to a person addicted to a μ agonist, butorphanol will induce an immediate onset of abstinence syndrome.

Side effects

Butorphanol has a different spectrum of side effects than μ opioid analgesics. Respiratory depression occurs. There is a lower ceiling on this effect, however, and it is not generally lethal, as is the case with high doses of μ agonists. Major side effects after normal analgesic doses are sedation, nausea, and sweating, as well as dysphoric (hallucinogenic) effects at higher doses. Butorphanol causes an increase in pulmonary arterial pressure and pulmonary vascular resistance. There is an overall increased workload on the heart, and it should not be used in patients with congestive heart failure or to treat pain from acute myocardial infarction. Butorphanol has low abuse potential and is not a scheduled drug.

Veterinary Drugs and Treatments

Approved indication for dogs is “. . . for the relief of chronic nonproductive cough associated with tracheobronchitis, tracheitis, tonsillitis, laryngitis and pharyngitis originating from inflammatory conditions of the upper respiratory tract” (Package Insert; Torbutrol?—Fort Dodge). It is also used in practice in both dogs and cats as a preanesthetic medication, analgesic, and as an antiemetic prior to cisplatin treatment (although not very effective in cats for this indication). Compared with other opiate analgesics, butorphanol is not very useful in small animals (particularly dogs) for treating pain and has to be dosed frequently.
The approved indication for horses is “. . . for the relief of pain associated with colic in adult horses and yearlings” (Package Insert; Torbugesic?—Fort Dodge). It has also been used clinically as an analgesic in cattle.